Patents Assigned to Affinium Pharmaceuticals, Inc.
  • Fab I inhibitors
    Patent number: 7250424
    Abstract: Compounds are disclosed which are Fab I inhibitors and are useful in the treatment bacterial infections.
    Type: Grant
    Filed: November 22, 2005
    Date of Patent: July 31, 2007
    Assignee: Affinium Pharmaceuticals, Inc.
    Inventors: Walter J. Burgess, Dalia R. Jakas, William F. Huffman, William H. Miller, Kenneth A. Newlander, Mark A. Seefeld, Irene N. Uzinskas
  • Purified polypeptides from
    Patent number: 7250285
    Abstract: The invention provides novel polypeptides and polynucleotides encoding such polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing such polypeptides to screen for antibacterial compounds.
    Type: Grant
    Filed: April 13, 2006
    Date of Patent: July 31, 2007
    Assignee: Affinium Pharmaceuticals, Inc.
    Inventors: Michael Terence Black, John Edward Hodgson, David Justin Charles Knowles, Michael Arthur Lonetto, Richard O Nicholas, Robert King Stodola, Martin Karl Russel Burnham
  • Novel polypeptides encoded by essential bacterial genes
    Publication number: 20070072192
    Abstract: The present invention relates to polypeptide targets for pathogenic bacteria. The invention also provides biochemical and biophysical characteristics of those polypeptides.
    Type: Application
    Filed: June 27, 2005
    Publication date: March 29, 2007
    Applicant: Affinium Pharmaceuticals, Inc.
    Inventors: Aled Edwards, Akil Dharamsi, Masoud Vedadi
  • Novel Purified dihydrodipicolinate synthase polypeptides and structures thereof
    Publication number: 20070048814
    Abstract: The present invention relates to novel drug targets for pathogenic bacteria. Accordingly, the invention provides purified protein comprising the amino acid sequence set forth in SEQ ID NO: 4. The invention also provides biochemical and biophysical characteristics of the polypeptides of the invention.
    Type: Application
    Filed: September 12, 2005
    Publication date: March 1, 2007
    Applicant: Affinium Pharmaceuticals, Inc.
    Inventors: Aled Edwards, Akil Dharamsi, Matthew Kimber
  • Compounds
    Patent number: 7176299
    Abstract: This invention relates to newly identified Staphylococcal polynucleotides, polypeptides encoded by such polynucleotides, the uses of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides and recombinant host cells transformed with the polynucleotides. This invention also relates to inhibiting the biosynthesis or action of such polynucleotides or polypeptides and to the use of such inhibitors in therapy.
    Type: Grant
    Filed: June 23, 2005
    Date of Patent: February 13, 2007
    Assignee: Affinium Pharmaceuticals, Inc.
    Inventors: Michael Terence Black, Martin Karl Russell Burnham, Jason Craig Fedon, John Edward Hodgson, David Justin Charles Knowles, Michael Arthur Lonetto, Richard Oakley Nicholas, Leslie Marie Palmer, Julie M. Pratt, Raymond Winfield Reichard, Martin Rosenberg, Christopher Michael Traini, Judith M. Ward, Richard Lloyd Warren
  • Crystal structures of YHHF polypeptides
    Publication number: 20070010949
    Abstract: The present invention relates to novel drug targets for pathogenic bacteria. Accordingly, the invention provides purified protein comprising the amino acid sequence set forth in SEQ ID NO: 4. The invention also provides biochemical and biophysical characteristics of the polypeptides of the invention.
    Type: Application
    Filed: June 30, 2005
    Publication date: January 11, 2007
    Applicant: Affinium Pharmaceuticals, Inc.
    Inventors: Aled Edwards, Akil Dharamsi, Masoud Vedadi, Matthew Kimber
  • Crystal structures of aspartate semialdehyde dehydrogenases
    Publication number: 20070004020
    Abstract: The present invention relates to novel drug targets for pathogenic bacteria. Accordingly, the invention provides purified protein comprising the amino acid sequence set forth in SEQ ID NO: 4. The invention also provides biochemical and biophysical characteristics of the polypeptides of the invention.
    Type: Application
    Filed: June 30, 2005
    Publication date: January 4, 2007
    Applicant: Affinium Pharmaceuticals, Inc.
    Inventors: Aled Edwards, Akil Dharamsi, Masoud Vedadi, Matthew Kimber, Robert Lam
  • Novel purified polypeptides from Staphylococcus aureus
    Publication number: 20060258845
    Abstract: The present invention relates to novel drug targets for pathogenic bacteria. Accordingly, the invention provides purified protein comprising the amino acid sequence set forth in SEQ ID NO: 4. The invention also provides biochemical and biophysical characteristics of the polypeptides of the invention.
    Type: Application
    Filed: January 11, 2006
    Publication date: November 16, 2006
    Applicant: Affinium Pharmaceuticals, Inc.
    Inventors: Donald Awrey, Teresa McGrath, Vladimir Romanov
  • Heterocyclic compounds, methods of making them and their use in therapy
    Publication number: 20060183908
    Abstract: In part, the present invention is directed to antibacterial compounds of formula (I) wherein A is a bicyclic heteroaryl ring or a tricyclic ring and R2 is an heterocyclic residue; L is a bond, or L is alkyl, alkenyl or cycloalkyl.
    Type: Application
    Filed: December 5, 2003
    Publication date: August 17, 2006
    Applicant: Affinium Pharmaceuticals, Inc.
    Inventors: Judd Berman, Peter Sampson, Heinz Pauls, Jailall Ramnauth, David Douglas, Matthew Surman, Dejian Xie, Helene Decornez
  • Compositions comprising multiple bioactive agents, and methods of using the same
    Publication number: 20060142265
    Abstract: In part, the present invention is directed to compositions comprising a FabI inhibitor and at least one other bioactive agent. In another part, the present invention is directed to antibacterial compositions comprising a compound of formulas I-III and at least one other antibacterial agent.
    Type: Application
    Filed: September 19, 2005
    Publication date: June 29, 2006
    Applicant: Affinium Pharmaceuticals, Inc.
    Inventors: Judd Berman, Molly Schmid, John Mendlein, Nachum Kaplan
  • FabK variant
    Patent number: 7056697
    Abstract: The invention provides FabK polypeptides and polynucleotides encoding FabK polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing FabK polypeptides to screen for antibacterial compounds.
    Type: Grant
    Filed: November 26, 2002
    Date of Patent: June 6, 2006
    Assignee: Affinium Pharmaceuticals, Inc.
    Inventors: Walter E. DeWolf, Jr., David John Payne, Nicola Gail Wallis, Joshua M. West
  • Methods of agonizing and antagonizing FabK
    Patent number: 7048926
    Abstract: The invention provides methods for using agonists and antagonists of FabK polypeptides, particularly to modulate the metabolism of bacteria or to treat bacterial infection.
    Type: Grant
    Filed: April 4, 2003
    Date of Patent: May 23, 2006
    Assignee: Affinium Pharmaceuticals, Inc.
    Inventors: Martin Brandt, Walter E. DeWolf, Jr., Paul M. Keller, Arunbhai H. Patel, David J. Payne, Shannon L. Reed, Mark A. Seefeld, David G. Tew, Nicola G. Wallis, Joshua M. West
  • Fab I inhibitors
    Patent number: 7049310
    Abstract: Compounds are disclosed which are Fab I inhibitors and are useful in the treatment bacterial infections.
    Type: Grant
    Filed: April 3, 2002
    Date of Patent: May 23, 2006
    Assignee: Affinium Pharmaceuticals, Inc.
    Inventors: Walter J. Burgess, Dalia Jakas, William F. Huffman, William H. Miller, Kenneth A. Newlander, Mark A. Seefeld, Irene N. Uzinskas
  • Essential novel bacterial polypeptides
    Publication number: 20060104989
    Abstract: The present invention relates to polypeptide targets for pathogenic bacteria. The invention also provides biochemical and biophysical characteristics of those polypeptides.
    Type: Application
    Filed: May 5, 2005
    Publication date: May 18, 2006
    Applicant: Affinium Pharmaceuticals, Inc.
    Inventors: Aled Edwards, Akil Dharamsi, Masoud Vedadi
  • FabK variant
    Patent number: 7033795
    Abstract: The invention provides FabK polypeptides and polynucleotides encoding FabK polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are preferred methods for utilizing FabK polypeptides and polynucleotides as diagnostic reagents and in diagnostic assays to screen for microbial infections in organisms and infestations in materials.
    Type: Grant
    Filed: November 26, 2002
    Date of Patent: April 25, 2006
    Assignee: Affinium Pharmaceuticals, Inc.
    Inventors: Walter E. DeWolf, Jr., David John Payne, Nicola Gail Wallis, Joshua M. West
  • Novel compounds
    Publication number: 20060083752
    Abstract: This invention relates to newly identified Staphylococcal polynucleotides, polypeptides encoded by such polynucleotides, the uses of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides and recombinant host cells transformed with the polynucleotides. This invention also relates to inhibiting the biosynthesis or action of such polynucleotides or polypeptides and to the use of such inhibitors in therapy.
    Type: Application
    Filed: June 23, 2005
    Publication date: April 20, 2006
    Applicant: Affinium Pharmaceuticals, Inc.
    Inventors: Michael Black, Martin Burnham, Jason Fedon, John Hodgson, David Knowles, Michael Lonetto, Richard Nicholas, Leslie Palmer, Julie Pratt, Raymond Reichard, Martin Rosenberg, Christopher Traini, Judith Ward, Richard Warren
  • Crystal structures of NH3-dependent NAD synthetases
    Publication number: 20060079669
    Abstract: The present invention relates to novel drug targets for pathogenic bacteria. Accordingly, the invention provides purified protein comprising the amino acid sequence set forth in SEQ ID NO: 4. The invention also provides biochemical and biophysical characteristics of the polypeptides of the invention.
    Type: Application
    Filed: June 30, 2005
    Publication date: April 13, 2006
    Applicant: Affinium Pharmaceuticals, Inc.
    Inventors: Aled Edwards, Akil Dharamsi, Masoud Vedadi, Matthew Kimber, Robert Lam
  • Novel purified hydroxymethylglutaryl-CoA reductases and structures thereof
    Publication number: 20060078974
    Abstract: The present invention relates to novel drug targets for pathogenic bacteria. Accordingly, the invention provides purified protein comprising the amino acid sequence set forth in SEQ ID NO: 4. The invention also provides biochemical and biophysical characteristics of the polypeptides of the invention.
    Type: Application
    Filed: September 16, 2005
    Publication date: April 13, 2006
    Applicant: Affinium Pharmaceuticals, Inc.
    Inventors: Aled Edwards, Akil Dharamsi, Klaus Fiebig, Robert Lam
  • Novel purified polypeptides from Enterococcus faecalis
    Publication number: 20060078977
    Abstract: The present invention relates to novel drug targets for pathogenic bacteria. Accordingly, the invention provides purified protein comprising the amino acid sequence set forth in SEQ ID NO: 4. The invention also provides biochemical and biophysical characteristics of the polypeptides of the invention.
    Type: Application
    Filed: June 27, 2005
    Publication date: April 13, 2006
    Applicant: Affinium Pharmaceuticals, Inc.
    Inventors: Aled Edwards, Akil Dharamsi, Masoud Vedadi, Teresa Clarke
  • Novel purified polypeptides from haemophilus influenzae
    Publication number: 20060078922
    Abstract: The present invention relates to novel drug targets for pathogenic bacteria. Accordingly, the invention provides purified protein comprising the amino acid sequence set forth in SEQ ID NO: 4. The invention also provides biochemical and biophysical characteristics of the polypeptides of the invention.
    Type: Application
    Filed: September 12, 2005
    Publication date: April 13, 2006
    Applicant: Affinium Pharmaceuticals, Inc.
    Inventors: Aled Edwards, Akil Dharamsi, Robert Lam